Bridge to Life
PrivateLast Round
Series C
Aug 12, 2026
Est. Valuation
$470M
Total Funding Raised
$237M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Bridge to Life is a biotechnology company that develops and markets innovative organ preservation and machine perfusion technologies to improve transplant outcomes.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Biotechnology, Biotech Equipment
Business Model
B2B
Customer Profile
Hardware Sales, Usage-Based SaaS
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Bridge to Life Comparables
Compare Bridge to Life with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Getinge AB | 86% | |
| Shanghai Genext Medical Technology Co., Ltd. | 82% | |
| Xvivo Perfusion | 81% |
Bridge to Life Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Aug 12, 2026 | ||||
| Series A Extension | Aug 28, 2024 | ||||
| Strategic | Aug 2, 2023 | ||||
| Debt | Aug 19, 2021 | ||||
| VC Round | Jan 21, 2009 |
Key People
Founding team and executive leadership
Bridge to Life Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Soleus Capital | Series C |
| Perceptive Advisors | Debt |
| Lauxera Capital Partners | Series C |
| Wisconsin Alumni Research Foundation | VC Round |
| SCRA | VC Round |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 12, 2026
$110M round led by Soleus Capital
- Mar 24, 2026
VitaSmart HOPE System received FDA clearance for US commercial use.
Bridge to Life Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Bridge to Life's valuation, stock price, and market status.
Is Bridge to Life a public or private company?
Bridge to Life is a private company.
What is the current stock price of Bridge to Life?
Bridge to Life is a private company, so its shares have no public market price. Caplight tracks Bridge to Life's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Bridge to Life worth (valuation)?
Bridge to Life's valuation is estimated at $470.0M based on funding round data.
Can I buy Bridge to Life stock?
Bridge to Life shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Bridge to Life's last funding round?
Bridge to Life's most recent funding round was Series C on August 12, 2026.
Who are the main investors in Bridge to Life?
Key investors in Bridge to Life include Soleus Capital, Perceptive Advisors.
Will Bridge to Life IPO soon?
No public IPO plans have been announced for Bridge to Life.
How can I track Bridge to Life secondary market activity?
Caplight tracks bids, offers, and trades in Bridge to Life's shares on secondary markets.